Want to cut your energy bills? Here’s how five experts are doing it 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
SAN FRANCISCO, March 06, 2017 -- Hagens Berman Sobol Shapiro LLP reminds investors in PixarBio Corporation (Other OTC:PXRB) of the March 27, 2017 Lead Plaintiff deadline in the pending securities class action.
If you purchased PXRB securities (1) pursuant to PixarBio’s private placement that closed on October 30, 2016 or (2) on the open market between October 30, 2016 and January 20, 2017 (the “Class Period”) and suffered over $25,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/PXRB
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On January 3, 2017, PixarBio CEO Frank Reynolds disclosed the Company’s intent to acquire InVivo Therapeutics Holdings Corp. In response, InVivo stated it had never been involved in negotiations with PixarBio and rejected the offer.
Then, on January 23, 2017, the SEC froze trading of PixarBio shares and stated, “the market for the security appears to reflect manipulative or deceptive activities.” Hagens Berman continues to investigate the SEC’s findings.
On February 8, 2017, the Company announced the resignation of Steven J. Chartier, its Chief Operating Officer and former VP of Regulatory Affairs. Mr. Chartier had been PixarBio’s COO for less than 2 months.
“We’re focused on the SEC’s ultimate determination of the matters warranting the trading halt and the damage inflicted on investors,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding PixarBio should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
